Investment & Finance
Series A / B / C Financing Rounds
In one line
Sequential priced equity rounds in venture-backed companies, typically progressing from product-market validation (A) to scale (B) to growth (C+).
Definition
Series A, B, C, and later rounds are sequential priced equity financings in venture-backed companies. Each Series corresponds to a new class of preferred stock with its own price, liquidation preference, and protective provisions. Series A typically funds product-market validation (in MedTech: feasibility study, IDE planning, early IP), Series B funds pivotal trial execution and regulatory clearance, and Series C+ funds commercial launch and scale. MedTech rounds tend to be larger and longer-spaced than software rounds because of trial timelines and capital intensity.
Why it matters
MedTech-specific dynamics: round timing usually maps to regulatory milestones (IDE, first-in-human, pivotal completion, FDA submission, FDA clearance, first revenue). Strategic investors (Medtronic, J&J, Boston Scientific corporate venture arms) often participate in B/C rounds and may negotiate ROFR or future M&A optionality.
Common pitfalls
- •Raising too little at Series A and being forced into a down round when a trial enrollment slips.
- •Optimizing for valuation over investor quality — strong leads pay dividends in later rounds.
Sources